GnRH analogue in assessing chronic pelvic pain in women with residual ovaries

Marcus Carey, Mark Slack
In: BJOG: An International Journal of Obstetrics & Gynaecology · 1996 · vol. 103(2) , pp. 150–153 · doi:10.1111/j.1471-0528.1996.tb09667.x · PMID:8616132 · W2087811990
article OA: closed CC0 ⤵ 16 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated whether GnRH analogue goserelin could differentiate pelvic pain causes in women with residual ovaries, finding that pain relief from goserelin correlated with surgical success.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To assess whether suppression of ovarian function by a gonadotrophin releasing hormone (GnRH) analogue could assist in the diagnosis of chronic pelvic pain in women with residual ovaries. DESIGN: Uncontrolled, observational study. SETTING: District general hospital (seven women) and teaching hospital (one woman). SETTING: Eight women with residual ovaries and chronic pelvic pain. INTERVENTIONS: Goserelin 3.6 mg every 28 days was used followed by surgery to remove residual ovaries. MAIN OUTCOME MEASURES: The women's response to goserelin and surgery (12 months or more post-operatively) was assessed clinically. RESULTS. Goserelin was associated with resolution of pelvic pain in the six women who obtained relief of pain with oophorectomy. The only woman who did not respond to goserelin also failed to gain relief with surgery. One woman who responded to goserelin declined surgery. CONCLUSIONS: Suppression of ovarian function by GnRH analogues may allow differentiation of pelvic pain caused by the residual ovary syndrome from other causes. This would enable selection of cases likely to benefit from surgery, avoiding potentially difficult surgery in women who will gain little or no relief of symptoms with surgery. Only eight cases are reported and a randomised controlled trial would be required to determine the place of GnRH agonists in the treatment of the residual ovary syndrome.

My notes (saved in your browser only)

Condition tags

chronic_pelvic_pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Cited by (8)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-09-29T06:34:56.587159+00:00
License: CC0 · commercial use OK